Feed - Buzzberg

15:01
Apr 16

@a_may_md

@plainyogurt21 In fact true differentiation is a NEGATIVE. How else can you be sure it’s going to work? What we really need is Q5Y dosing.

15:00
Apr 16

@a_may_md

@plainyogurt21 True differentiation is meaningless. YTE slop proves this. (Not /s but /rage)

00:45
Apr 16

@a_may_md

@TheCinesthetic @TarsusRx @RealGDT collab pls?

23:22
Apr 15

@a_may_md

@Biohazard3737 I thought you guys had this figured out?

23:10
Apr 15

@a_may_md

@DA_Capital_ Much more accurate

21:46
Apr 15

@a_may_md

@Jul05310473John I’ve generally made my returns on the exact opposite

14:53
Apr 15

@a_may_md

@avidresearch The clinical trial data discussion portion of the meeting: https://t.co/cyqKSyluH3

14:19
Apr 15

@a_may_md

@LizzyLaw_ Good test of whether or not the agency actually still does what it purports to do.

20:11
Apr 14

@a_may_md

@BiotechPort @BayAreaBiotechI Your “solid” group has been much more than just “solid”. Awesome work! 👏🏻

12:56
Apr 14

@a_may_md

@Mykalt45 @CrossBridgeBio Congrats, great work!

02:25
Apr 14

@a_may_md

@AbudBakri @maxmarchione is going to run an RCT

22:16
Apr 13

@a_may_md

@TomSteyer You are obligated to start directly providing it to people immediately.

21:38
Apr 13

@a_may_md

@CloisterRes @STL_Biotech Careful that’ll make your hair fall out

20:04
Apr 13

@a_may_md

@LocasaleLab I’m curious why you haven’t solved the pancreatic cancer OS problem yourself?

15:14
Apr 13

@a_may_md

@lfholt It was already up 300% in the last year coming into today! Back to mid/low $50s imo, which before today would still have been an a…

15:02
Apr 13

@a_may_md

@lfholt SYRE may do well in the longer run, but there’s absolutely zero reason any company should ever add >$1B in market cap on small n …

SYRE

HIGH

14:06
Apr 13

@a_may_md

$SYRE is adding like 2-3 entire $PALI market caps on their open label data with a fully validated target. Timelines are different, obviou…

PALI

MED

14:05
Apr 13

@a_may_md

$PALI $SYRE 🤷‍♂️🤷‍♂️🤷‍♂️🤷‍♂️🤷‍♂️🤷‍♂️🤷‍♂️🤷‍♂️

13:41
Apr 13

@a_may_md

@slk349390919 Certainly not a secondary indication when pursuing a target that is literally only expressed in the gut

13:35
Apr 13

@a_may_md

$SYRE +40% at open? Glad to #short that.

SYRE

MED

12:27
Apr 13

@a_may_md

@celinefw20 What like the 12th TL1a mab?

12:25
Apr 13

@a_may_md

@Antifunbw This post is not a dunk on anybody - it's purely a response to illiquid premarket price action in the stock market

12:21
Apr 13

@a_may_md

Kind of another one of those "do I really have to post about this?" things, but FWIW, $ABVX has absolutely no reason AT ALL to be concerned …

ABVX SYRE

HIGH

11:17
Apr 13

@a_may_md

@adamfeuerstein Would be very silly if so. Here’s the $ABVX press release of P2a data…..from EIGHT years ago https://t.co/ERGBkYRR5z

01:42
Apr 13

@a_may_md

@buysidebio Press release headline

01:01
Apr 13

@a_may_md

@maxmarchione This is not a clinical trial protocol. Write a clinical trial protocol.

00:11
Apr 13

@a_may_md

@maxmarchione Run a trial. Have them fund it. Run a trial.

00:09
Apr 13

@a_may_md

@CloisterRes God forbid an egg white get a little flavor smh

18:34
Apr 10

@a_may_md

@JCanNuSH Grifters

18:09
Apr 10

@a_may_md

@JWinnfields @Biotenic Would have to do cash/fd share calculations to give you a solid answer so idk sorry

17:42
Apr 10

@a_may_md

@cwhogg https://t.co/ehFXVbkZG6

17:35
Apr 10

@a_may_md

@pitdesi Polymarket odds 99.999% in your favor

17:21
Apr 10

@a_may_md

@JWinnfields @Biotenic https://t.co/QsTHx6sc7M

17:19
Apr 10

@a_may_md

@myrahahmad @ManOnThePen West coast detected https://t.co/3p2zQIVSPt

17:07
Apr 10

@a_may_md

@JWinnfields @Biotenic From $4.76 where it’s halted? Absolutely

16:36
Apr 10

@a_may_md

@ManOnThePen @myrahahmad

16:00
Apr 10

@a_may_md

@Biotenic Do you not recognize an 80x-down OPPORTUNITY* (!!!!) when you see one?!?!!?

16:49
Apr 08

@a_may_md

You'll never guess which of these two dosing intervals Wedbush says "may not be viable" for $NKTR Rezpeg moving forward. Won't mince words …

13:23
Apr 07

@a_may_md

$SNY next-gen atopic dermatitis drug failed in P2b. Missed primary endpoint. MOA was IL13xTSLP. Now what have they got to follow up dup…

01:29
Apr 07

@a_may_md

When the 10b5-1 dumps 75% of the CFO’s stake in a single transaction… $HIMS https://t.co/PzJ8IuSh8u https://t.co/M1Eu658jcL

15:14
Apr 06

@a_may_md

“Boss, the report actually said grave, not cave” https://t.co/gHB3xReMyt

15:09
Apr 06

@a_may_md

Adding more $TENX anecdotes at this point just for sheer comedic value. Let's check in on what is being said about how these very sick seve…

19:19
Apr 04

@a_may_md

51.5% of you thought that $NVO was going to be delisted on $LLY Orforligpron approval day. It was not delisted. Not even a little bit. Ar…

15:23
Apr 03

@a_may_md

Aside from the childlike levels of logic used and idiotic strawman arguments, my favorite part is how what this dude is saying actually just…

14:58
Apr 03

@a_may_md

This clip must go hard if you have a room temperature IQ. https://t.co/VOW4iQ41hc

15:50
Apr 01

@a_may_md

Foundayo $LLY $NVO

LLY NVO

15:41
Apr 01

@a_may_md

You’ve only got until close to submit your votes now $NVO $LLY

NVO LLY

15:34
Apr 01

@a_may_md

https://t.co/OUKIFQRh4R

15:32
Apr 01

@a_may_md

AAAAAAAAAAAAAHHHHHHHHHHHHHHHHHHHHHHGHHHGHHJHJVAG $NVO $LLY https://t.co/MowC1cd2cQ https://t.co/78HVjBpY7S

LLY NVO

13:43
Apr 01

@a_may_md

On the day that $LLY orforglipron gets approved, $NVO will trade down:

LLY NVO